Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.1% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 19,714 shares of the life sciences company’s stock after acquiring an additional 1,134 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Illumina were worth $6,125,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 83.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 39 shares during the last quarter. Financial Advocates Investment Management increased its holdings in Illumina by 1,430.0% during the 4th quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 572 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in Illumina by 61.7% during the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. C J Advisory Inc purchased a new stake in Illumina during the 1st quarter worth approximately $29,000. Finally, Lake Point Wealth Management purchased a new stake in Illumina during the 4th quarter worth approximately $30,000. 90.80% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:ILMN traded up $6.36 during midday trading on Wednesday, reaching $312.83. 627,400 shares of the company traded hands, compared to its average volume of 976,958. Illumina, Inc. has a twelve month low of $261.61 and a twelve month high of $372.61. The firm has a market capitalization of $45.22 billion, a P/E ratio of 54.69, a P/E/G ratio of 2.14 and a beta of 1.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.34 by $0.26. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The business had revenue of $846.00 million during the quarter, compared to analyst estimates of $838.70 million. During the same quarter in the previous year, the firm posted $1.45 EPS. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. Research analysts anticipate that Illumina, Inc. will post 6.68 EPS for the current fiscal year.
In other Illumina news, SVP Aimee L. Hoyt sold 298 shares of the business’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $304.63, for a total transaction of $90,779.74. Following the completion of the transaction, the senior vice president now owns 2,297 shares in the company, valued at approximately $699,735.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mostafa Ronaghi sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $305.49, for a total value of $3,054,900.00. Following the transaction, the senior vice president now owns 87,414 shares of the company’s stock, valued at approximately $26,704,102.86. The disclosure for this sale can be found here. Insiders have sold a total of 50,329 shares of company stock valued at $15,648,675 in the last 90 days. Insiders own 0.38% of the company’s stock.
A number of brokerages have recently weighed in on ILMN. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $355.00 price target for the company in a report on Tuesday, April 2nd. OTR Global downgraded Illumina to a “positive” rating in a report on Tuesday, April 2nd. Bank of America reiterated a “buy” rating and issued a $355.00 price target on shares of Illumina in a report on Wednesday, January 30th. Finally, Deutsche Bank downgraded Illumina from a “buy” rating to a “hold” rating and set a $296.53 price target for the company. in a report on Friday, January 25th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $353.58.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Read More: Green Investing
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.